Executive Summary
The overnight filing cycle from July 2-3, 2026, reveals a market dominated by corporate actions, merger approvals, and mixed earnings signals. A key theme is the significant shareholder and creditor approval for the Dr. Agarwal's Eye Hospital and Dr. Agarwal's Health Care amalgamation, moving it closer to final NCLT sanction. However, minority opposition (48.10% against) at Dr.
Agarwal's Eye Hospital highlights governance friction. On the earnings front, a clear divergence is visible: JSW Steel reported a massive 631% YoY PAT surge, while Nucleus Software saw a 28% PAT decline despite revenue growth, indicating severe margin compression. The steel sector shows robust demand (JSW Steel +10% revenue, Rajratan Global Wire +24% revenue), but margin pressures are evident from rising raw material costs. The banking sector, represented by Union Bank of India, shows healthy YoY loan growth (+12.5%) but a QoQ deposit decline (-1.8%), signaling potential liquidity tightness. Several smaller companies (Dipna Pharmachem, Riba Textiles) are reporting sharp segmental divergences and operational stress, creating a mixed picture for the broader market.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance · M&A · Insolvency · Company update · Corporate action
Tracking the trend? Catch up on the prior India Pre-Market Regulatory Roundup digest from June 26, 2026.
Investment Signals (10)
- JSW Steel ↓ (BULLISH)▲
Consolidated PAT surged 631% YoY to ₹25,508 Cr on 10% revenue growth to ₹1,85,470 Cr, with net debt reduction of ~₹22,693 Cr. The company is proposing a ₹7,000 Cr QIP, signaling confidence in growth.
- Union Bank of India ↓ (BULLISH)▲
Gross advances grew 12.50% YoY and CASA ratio improved 259 bps YoY to 35.10%, indicating strong liability franchise and credit growth.
- Rajratan Global Wire ↓ (MIXED)▲
Revenue grew 24% YoY to ₹1,15,650 Lakh, driven by exports and Chennai facility. However, EBITDA margin compressed 147 bps to 12.10% and Debt/EBITDA worsened to 2.31x from 1.87x.
- Nucleus Software Exports ↓ (BEARISH)▲
Revenue grew only 5.26% YoY while EBITDA fell 25.92% and PAT dropped 28.38%. Employee costs rose 10.24% and other expenses surged 24.59%, crushing margins.
- Dipna Pharmachem ↓ (BEARISH)▲
Annual net profit surged 170.2% YoY, but this masks a Q4 revenue collapse to ₹202.49 Lakh from ₹5,351.72 Lakh in Q3. The Chemicals segment swung to a ₹512.35 Lakh loss from a ₹124.30 Lakh profit.
- Dr. Agarwal's Health Care ↓ (BULLISH)▲
Shareholders (99.97% in favor) and secured creditors approved the amalgamation scheme, clearing a major regulatory hurdle. This consolidation could unlock significant synergies.
- Parmax Pharma ↓ (BULLISH)▲
Shareholders approved a 67% increase in authorized capital (to ₹10 Cr) and preferential issuance of 31.37 Lakh shares and 21.45 Lakh warrants, indicating a major capital raise and potential expansion.
- Texmaco Rail & Engineering ↓ (BULLISH)▲
Secured a ₹26.56 Cr contract for signalling and Kavach (train collision avoidance) system from South Central Railway, adding to a strong order book of ₹1,159.94 Cr.
- IndusInd Bank ↓ (NEUTRAL)▲
Promoters restructured pledges without changing total encumbrance (42.78% of promoter holding), but the security cover ratio of 1.31:1 is thin, warranting monitoring.
- Reliance Power ↓ (BEARISH)▲
Received a ₹2.44 Cr income tax penalty for FY 2016-17. While immaterial, the recurring nature of such tax disputes is a governance overhang.
Risk Flags (10)
- Nucleus Software/Margin Collapse↓ [HIGH RISK]▼
EBITDA margin crashed from 20.14% to 14.17% YoY, and PAT margin from 19.59% to 13.33%. Employee costs (+10.24%) and other expenses (+24.59%) are outpacing revenue growth significantly.
- Dipna Pharmachem/Q4 Revenue Cliff↓ [HIGH RISK]▼
Quarterly revenue collapsed 96.2% QoQ to ₹202.49 Lakh from ₹5,351.72 Lakh. The Chemicals segment is in a full-year loss of ₹512.35 Lakh. This is a severe operational discontinuity.
- Riba Textiles/Deteriorating Financial Health↓ [HIGH RISK]▼
Operating income declined 13.7% YoY, total debt increased 23.6% YoY, operating cycle elongated to 95 days from 72 days, and interest coverage declined to 3.50x.
- Rajratan Global Wire/Leverage Increase↓ [MEDIUM RISK]▼
Debt/EBITDA increased to 2.31x from 1.87x on higher borrowings for working capital and capex, while RoCE moderated to 13.53% from 14.72%.
- Union Bank of India/QoQ Deposit Decline↓ [MEDIUM RISK]▼
Total deposits declined 1.80% QoQ and CASA deposits fell 2.12% QoQ, even as advances grew. This could signal funding pressure and margin compression.
- Dr. Agarwal's Eye Hospital/Minority Opposition [MEDIUM RISK]▼
48.10% of public shareholders voted against the amalgamation scheme, indicating significant governance concerns or valuation disagreement.
- IndusInd Bank/High Promoter Pledging↓ [MEDIUM RISK]▼
Promoter encumbrance remains high at 42.78% of promoter shareholding. While restructured, the thin 1.31:1 security cover ratio is a risk if share prices decline.
- Reliance Power/Tax Penalty↓ [LOW RISK]▼
A ₹2.44 Cr penalty for FY 2016-17 under Section 271(1)(c) adds to the company's legacy of regulatory and tax disputes.
- Delhivery/GST Demand↓ [LOW RISK]▼
Received a tax demand of ₹66.11 Lakh for FY 2023-24 for disallowance of input tax credit. While immaterial, it signals potential compliance gaps.
- Pajson Agro India/Regulatory Fine↓ [LOW RISK]▼
BSE levied a ₹5,000 fine for a one-day delay in filing related party transaction data. While small, it indicates weak compliance processes.
Opportunities (8)
- JSW Steel/Value-Added Products↓ (OPPORTUNITY)◆
VASP sales grew 14% to 17.57 MnT, outpacing overall volume growth of 12%. The company is shifting to higher-margin products, which could sustain profitability even if commodity prices fluctuate.
- Texmaco Rail & Engineering/Railway Capex Play↓ (OPPORTUNITY)◆
New order for Kavach (indigenous train protection system) positions the company to benefit from the government's massive railway safety and modernization push. Order book of ₹1,159.94 Cr provides strong revenue visibility.
- Nucleus Software Exports/Dividend Yield Play↓ (OPPORTUNITY)◆
Despite earnings decline, the company proposed a ₹12.50/share final dividend. With cash equivalents of ₹414.14 Cr (46% of shareholders' funds) and a debt-free status, the downside is cushioned.
- Union Bank of India/PSU Re-rating↓ (OPPORTUNITY)◆
Strong YoY growth in RAM advances (+11.56%) and a 714 bps YoY improvement in C/D ratio to 83.38% suggest improving operational efficiency. The QoQ deposit blip may be an entry point.
- Dr. Agarwal's Health Care/Merger Arbitrage↓ (OPPORTUNITY)◆
With all shareholder and creditor approvals secured, the scheme now moves to NCLT for final sanction. The near-unanimous support (99.97%) de-risks the deal, making it a low-risk catalyst.
- Parmax Pharma/Capital Raise for Growth↓ (OPPORTUNITY)◆
The 67% increase in authorized capital and preferential issuance of shares and warrants suggest a significant expansion plan. The 100% shareholder approval indicates strong promoter alignment.
- Rajratan Global Wire/Export Growth↓ (OPPORTUNITY)◆
Exports contributed 17% of revenues, and the company is expanding capacity (1,92,000 TPA total). The US tariff reduction on textiles (from 50% to 10%) could provide a tailwind for the sector.
- Bajaj Electricals/New CMO Appointment↓ (OPPORTUNITY)◆
Appointment of Tiny Sengupta (ex-J&J) as CMO could signal a renewed focus on brand building and consumer marketing, potentially driving growth in the consumer durables segment.
Sector Themes (5)
- Steel Sector: Volume Growth vs. Margin Squeeze◆
Both JSW Steel (+10% revenue, +631% PAT) and Rajratan Global Wire (+24% revenue) show strong demand, but Rajratan's margin compression (-147 bps) and higher leverage (Debt/EBITDA 2.31x) highlight that rising raw material costs are eating into profits. JSW's massive PAT jump is partly base-effect driven. [IMPLICATION: Favor large, integrated players with better cost control.]
- Banking Sector: YoY Strength, QoQ Liquidity Concerns◆
Union Bank of India's 12.5% YoY loan growth is healthy, but the QoQ deposit decline (-1.8%) and CASA dip (-2.12% QoQ) suggest banks are facing funding challenges. This could lead to NIM compression if deposit competition intensifies. [IMPLICATION: Monitor deposit growth and CASA ratios closely.]
- Healthcare Consolidation Wave◆
The Dr. Agarwal's group merger is progressing smoothly through NCLT, with all creditor and shareholder classes approving. This reflects a broader trend of consolidation in the organized healthcare sector to achieve scale and cost efficiencies. [IMPLICATION: Watch for other hospital chains announcing similar mergers.]
- Small-Cap Earnings Divergence◆
Companies like Dipna Pharmachem and Riba Textiles are showing extreme volatility in quarterly performance—Dipna's Q4 revenue collapsed 96% QoQ, while Riba's operating income fell 13.7% YoY. This highlights the high risk in small-cap names with concentrated business models. [IMPLICATION: Favor larger, more diversified companies in the current environment.]
- Corporate Governance Scrutiny Intensifying◆
The 48.10% public shareholder opposition at Dr. Agarwal's Eye Hospital and the inadvertent voting by promoters at Balkrishna Paper Mills (leading to 9,005 votes being invalidated) show that governance issues are being increasingly flagged by minority shareholders. [IMPLICATION: Companies with weak governance practices may face higher cost of capital.]
Watch List (8)
-
AGM on July 24, 2026, will vote on a ₹7,000 Cr QIP. Watch for the issue price and investor response. Also monitor global steel prices. [Date: July 24, 2026]
-
With all approvals in place, the scheme now goes for final NCLT sanction. Any delays or conditions imposed by NCLT could impact the timeline. [Date: Ongoing]
-
Board meeting on August 7, 2026, to consider Q1 FY27 results and an interim dividend. Record date for dividend is August 13, 2026. Watch for demand trends in FMCG. [Date: August 7, 2026]
-
AGM on July 27, 2026, to approve the ₹12.50 dividend. Record date is July 10, 2026. Watch for management commentary on margin recovery. [Date: July 27, 2026]
-
AGM on July 29, 2026. Watch for commentary on the impact of the BIOSECURE Act and destocking headwinds. The company's forward guidance will be critical. [Date: July 29, 2026]
-
The QoQ deposit decline needs monitoring. Watch for any commentary on deposit mobilization strategies and NIM outlook in the upcoming quarterly results. [Date: Q1 FY27 Results]
-
AGM on July 24, 2026. Watch for management's outlook on raw material costs and margin recovery, given the 147 bps margin compression. [Date: July 24, 2026]
-
With promoter encumbrance at 42.78% and a thin 1.31:1 security cover, any significant drop in the stock price could trigger margin calls. Monitor promoter actions. [Date: Ongoing]
Filing Analyses
(50)
02-07-2026
Decillion Finance Ltd. announced the appointment of M/s MGSA & Company as statutory auditors for FY 2026-27 to fill a casual vacancy after the resignation of previous auditors M/s T D K & Co., and appointed Mrs. Nita Agarwal as an Additional Non-Executive Independent Director effective July 2, 2026. Both appointments are subject to shareholder approval within three months. No financial results or performance metrics were disclosed in this filing.
- · Previous auditors M/s T D K & Co. resigned, creating a casual vacancy.
- · M/s MGSA & Company holds a clean ICAI Peer Review Certificate (No. 022043) valid until August 31, 2028.
- · Mrs. Nita Agarwal holds no shares in the company and has no relationships with other directors.
- · Board meeting lasted 30 minutes (7:00 PM to 7:30 PM).
02-07-2026
Deep Health AI India Limited (formerly Deep Diamond India Limited) held a board meeting on July 2, 2026, where it approved the calling of an Extraordinary General Meeting (EGM) on July 30, 2026, at 3:00 PM at the registered office. The board also approved the draft notice for the EGM. No financial results or operational metrics were disclosed in this filing.
- · The company has changed its name from Deep Diamond India Limited to Deep Health AI India Limited.
- · The EGM is scheduled for July 30, 2026, at 3:00 PM at the registered office in Udaipur, Rajasthan.
- · The board meeting was conducted via video conferencing and lasted from 5:30 PM to 8:25 PM.
02-07-2026
Parmax Pharma Limited held an Extraordinary General Meeting (EGM) on July 2, 2026, where all four proposed resolutions were passed with overwhelming shareholder support. The resolutions included increasing the authorized share capital, adopting a new set of articles of association, and approving two preferential issues: 31,37,586 equity shares and 21,45,145 convertible warrants to non-promoter category persons. While all resolutions passed unanimously with 100% votes in favour from those polled, only 62.44% of total outstanding shares were voted, indicating moderate shareholder participation.
- · The EGM was held on July 2, 2026, with 2,381 shareholders on record.
- · Only 16 shareholders attended the meeting via video conferencing (2 promoters, 14 public).
- · Resolution 1 (Ordinary): Increase in authorized share capital and alteration of capital clause — passed with 23,36,152 votes in favour, 1 against.
- · Resolution 2 (Special): Adoption of new articles of association — passed unanimously with 23,36,153 votes in favour, 0 against.
- · Resolution 3 (Special): Preferential issue of 31,37,586 equity shares to non-promoter category — passed with 23,36,147 votes in favour, 0 against.
- · Resolution 4 (Special): Preferential issue of 21,45,145 convertible warrants to non-promoter category — passed with 23,36,153 votes in favour, 0 against.
- · Promoter group voted 100% in favour on all resolutions, while public non-institutional voter turnout was only 45.72% of their eligible shares.
02-07-2026
Inventurus Knowledge Solutions Limited updated its disclosure regarding the acquisition of TruBridge, Inc. via its wholly-owned subsidiary IKS Inc., reducing the proposed financing facilities from up to USD 670,000,000 to up to USD 635,000,000. The Board also approved additional security interests, including a pledge over shares of Healthcare Resource Group, Inc. (HRG Inc.), a guarantee by HRG Inc., and security over inter-company debts, all subject to shareholder approval. The acquisition and related financing remain on track, with the reduction in facility size indicating a more conservative capital structure.
- · The Board meeting commenced at 6:05 p.m. IST and concluded at 6:26 p.m. IST on July 2, 2026.
- · HRG Inc. will become a material subsidiary of the Company upon consummation of the acquisition.
- · Additional security includes a pledge over the entire ownership interest of Target in HRG Inc., a corporate guarantee by HRG Inc., and security over inter-company debts from IKS Inc., IKS Cares Foundation, and Arai Solutions Private Limited.
- · Non-disposal undertakings were approved for shares of Aquity Solutions India Private Limited and TruBridge Healthcare Private Limited.
02-07-2026
Laurus Labs Limited held its 21st Annual General Meeting on July 2, 2026, where all nine resolutions were passed with requisite majority. Key approvals included the adoption of audited financial statements for FY2025-26, ratification of interim dividends totaling ₹2.00 per share (₹0.80 first interim and ₹1.20 second interim), re-appointment of directors Krishna Chaitanya Chava and Soumya Chava, appointment of two new independent directors (Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee), and approval of remuneration for non-executive and cost auditors. The meeting was conducted via video conferencing with 1,189 members participating, representing 40,55,06,345 shares.
- · All nine resolutions were passed with over 99% votes in favour, except Resolution 4 (re-appointment of Krishna Chaitanya Chava) which received 99.2855% and Resolution 5 (re-appointment of Soumya Chava) which received 99.2890%.
- · The meeting lasted 57 minutes, from 3:00 PM to 3:57 PM IST.
- · Remote e-voting was open from June 29, 2026 (9:00 AM IST) to July 1, 2026 (5:00 PM IST).
- · The cut-off date for voting rights was June 25, 2026.
- · The statutory auditors (Deloitte Haskins & Sells LLP) and the scrutinizer (RPR & Associates) were present.
02-07-2026
Union Bank of India reported provisional business data for the quarter ended June 30, 2026, showing YoY growth in gross advances (+12.50%) and domestic advances (+13.11%), with CASA deposits up 11.72% YoY. However, on a QoQ basis, total deposits declined 1.80% and CASA deposits fell 2.12%, while the overall business remained nearly flat (-0.24% QoQ).
- · RAM Advances (Domestic) grew 11.56% YoY to ₹6,08,095 Cr.
- · Domestic CASA ratio improved 259 bps YoY to 35.10%, but declined 11 bps QoQ.
- · Domestic C/D ratio (excluding bank deposits) improved 714 bps YoY to 83.38%.
- · The data is provisional and subject to review by statutory auditors and other approvals.
02-07-2026
Laurus Labs Limited held its 21st Annual General Meeting on July 2, 2026, where all nine resolutions were passed with requisite majority. The resolutions included adoption of audited financial statements for FY2025-26, ratification of two interim dividends totaling ₹2.00 per share (₹0.80 and ₹1.20), re-appointment of directors Krishna Chaitanya Chava and Soumya Chava, and appointment of two new independent directors. The meeting was conducted via video conferencing with 108 members representing 14,16,89,612 shares in attendance, and voting results showed overwhelming shareholder support with over 99% approval on all resolutions.
- · The meeting lasted 57 minutes (3:00 PM to 3:57 PM IST).
- · Remote e-voting was open from June 29, 2026 (9:00 AM) to July 1, 2026 (5:00 PM).
- · Cut-off date for voting rights was June 25, 2026.
- · An additional 30 minutes were allowed for e-voting during the AGM.
- · Votes were unblocked at 4:30 PM IST on July 2, 2026.
- · Resolution 4 (re-appointment of Krishna Chaitanya Chava) had the highest opposition at 0.7145% (28,97,326 shares against).
- · Resolution 5 (re-appointment of Soumya Chava) had 0.7110% opposition (28,83,281 shares against).
- · All other resolutions had negligible opposition (less than 0.25%).
02-07-2026
Parmax Pharma Limited has amended its Memorandum of Association to increase authorized share capital from ₹6,00,00,000 (₹6 Crore) to ₹10,00,00,000 (₹10 Crore), and adopted a new set of Articles of Association to align with the Companies Act, 2013. These changes were approved by shareholders at an Extraordinary General Meeting (EGM) held on July 2, 2026, and are disclosed under Regulation 30 of SEBI Listing Regulations.
- · The increase in authorized share capital is from ₹6,00,00,000 (60,00,000 equity shares of ₹10 each) to ₹10,00,00,000 (1,00,00,000 equity shares of ₹10 each).
- · The new Articles of Association replace the existing AOA which was based on the Companies Act, 1956, to comply with the Companies Act, 2013.
- · The amended MOA and new AOA are available on the company's website at www.parmaxpharma.com.
02-07-2026
CDG Petchem Limited has been renamed to Jujhar Logistics Limited, effective July 2, 2026, following receipt of a fresh Certificate of Incorporation from the Registrar of Companies. The name change reflects a strategic repositioning towards the logistics sector, as indicated by the new name 'Jujhar Logistics Limited'.
- · The fresh Certificate of Incorporation was issued by the Registrar of Companies, Central Processing Centre, Manesar.
- · The new company CIN is L52290TG2011PLC072532, which remains unchanged.
- · The registered office remains at Plot No 10 & 11, MCH No 1-8-304 to 307/10, Pattigadda Road, Hyderabad, Telangana, India-50003.
- · The new business nature is in logistics, as implied by the new name 'Jujhar Logistics Limited' and the CIN prefix L (Logistics).
02-07-2026
Texmaco Rail & Engineering Limited received a Letter of Acceptance from South Central Railway for a contract worth ₹26.56 crore for Comprehensive Signalling and Telecommunication works, including Automatic Block Signalling and Kavach. This new order brings the outstanding order book of the company's Infra Rail & Green Energy division to ₹1,159.94 crore (inclusive of taxes). The contract is to be executed within 12 months.
- · Contract execution timeline: within 12 months from date of Letter of Acceptance.
- · Order is domestic, awarded by South Central Railway.
- · No promoter/group interest or related party transaction involved.
- · Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
02-07-2026
IndusInd Bank's promoters, IndusInd International Holdings Limited (IIHL) and IndusInd Limited (IL), have restructured their pledged shareholdings as part of a refinancing of existing indebtedness. IIHL released a pledge on 1,12,88,989 shares (1.45% of total capital) on June 30, 2026, while IL simultaneously created a pledge on the same number of shares (1,12,88,989 shares, 1.45% of total capital). The total promoter encumbrance remains high at 42.78% of promoter shareholding, though the restructuring did not change the overall promoter shareholding of 15.08%.
- · The total promoter shareholding remains unchanged at 11,75,16,010 shares (15.08% of total share capital).
- · The total number of encumbered promoter shares remained unchanged at 5,02,67,535 shares (6.45% of total share capital).
- · The value of shares on the date of the event was ₹40,21,40,28,000, against an amount involved of ₹30,60,00,00,000, resulting in a security cover ratio of 1.31:1.
- · The end use of the borrowed amount is for 'refinancing of existing indebtedness'.
- · The encumbrance is not related to any debt instruments like debentures, commercial paper, or certificates of deposit.
- · The encumbered shares are 42.78% of promoter shareholding, which is less than 50%, and 6.45% of total share capital, which is less than 20%.
02-07-2026
Dipna Pharmachem Limited reported audited standalone financial results for Q4 and FY ended March 31, 2026. Annual revenue from operations grew 3.3% YoY to ₹12,908.33 Lakhs, while net profit surged 170.2% to ₹263.19 Lakhs. However, the Chemicals segment posted a full-year loss of ₹512.35 Lakhs, contrasting with a profit of ₹124.30 Lakhs in the prior year, and operating cash flow remained deeply negative at ₹(1,832.23) Lakhs.
- · The company adopted IND AS for the first time during the period.
- · The company has two reportable segments: Steel and Chemicals.
- · Steel segment revenue surged 348.5% YoY to ₹7,089.14 Lakhs, while Chemicals segment revenue declined 46.7% YoY to ₹5,819.19 Lakhs.
- · Chemicals segment posted a full-year loss of ₹512.35 Lakhs, compared to a profit of ₹124.30 Lakhs in FY25.
- · Steel segment profit jumped to ₹866.83 Lakhs from ₹17.72 Lakhs in FY25.
- · Operating cash flow worsened to ₹(1,832.23) Lakhs from ₹(919.46) Lakhs in FY25.
- · Total assets increased 55.3% to ₹20,562.94 Lakhs, driven largely by a surge in other current assets to ₹6,256.80 Lakhs (from ₹1,575.53 Lakhs).
- · Total outstanding dues to micro and small enterprises more than doubled to ₹9,210.18 Lakhs.
- · The company raised ₹1,827.01 Lakhs through share warrants during the year.
- · Paid-up equity share capital increased 9.3% to ₹2,628.92 Lakhs, partly due to a preferential issue.
- · Earnings per share (basic) for FY26 stood at ₹1.00, up from ₹0.41 in FY25.
- · No exceptional items were reported for either period.
- · The company does not have any subsidiary.
02-07-2026
Godrej Consumer Products Limited has announced a Board Meeting scheduled for August 7, 2026, to consider the unaudited financial results for the quarter ended June 30, 2026, and to evaluate the declaration of an interim dividend. If declared, the record date for the dividend will be August 13, 2026.
- · Board Meeting date: August 7, 2026
- · Record date for interim dividend (if declared): August 13, 2026
- · Compliance with SEBI Listing Regulations 29 and 42
02-07-2026
Dipna Pharmachem reported audited standalone results for Q4 and FY26, with total income for the year at ₹12,910.87 Lakhs (~₹129.11 Cr), up 3.34% YoY from ₹12,492.99 Lakhs. Net profit for FY26 surged 170.2% to ₹263.19 Lakhs from ₹97.40 Lakhs in FY25, driven by a significant improvement in the Steel segment and higher other income. However, the Chemicals segment posted a full-year loss of ₹512.35 Lakhs versus a profit of ₹124.30 Lakhs last year, and revenue from operations declined 2.9% YoY, indicating mixed segmental performance.
- · The company has two reportable segments: Chemicals and Steel.
- · Chemicals segment posted a loss of ₹512.35 Lakhs in FY26, a sharp reversal from a profit of ₹124.30 Lakhs in FY25.
- · Steel segment profit surged to ₹866.83 Lakhs in FY26 from ₹17.72 Lakhs in FY25.
- · Total assets increased to ₹20,562.94 Lakhs as at March 2026 from ₹13,238.03 Lakhs a year earlier, driven largely by a rise in inventories and other current assets.
- · Other current assets as at March 2026 stood at ₹6,256.80 Lakhs (from ₹1,575.53 Lakhs in March 2025).
- · Share warrant money received was ₹1,827.01 Lakhs during FY26.
- · Cash generated from operations was negative ₹1,832.23 Lakhs in FY26, compared to negative ₹919.46 Lakhs in FY25.
- · Net cash flow from financing was positive ₹1,880.03 Lakhs (vs negative ₹423.79 Lakhs in FY25), due to proceeds from equity/warrant issuances.
- · Earnings per share (basic) for FY26: ₹1.00 (up from ₹0.41 in FY25).
- · The company adopted IND AS for the first time during FY26.
02-07-2026
Syngene International Limited published its Annual Report for FY 2025-26 and convened its 33rd Annual General Meeting (AGM) on July 29, 2026 via video conferencing. The company reported revenue from operations of ₹37,387 Mn and a Profit After Tax of ₹3,799 Mn (before exceptional items), with a total workforce of 8,373. While the underlying business (excluding destocking effects) showed resilient mid-to-high-single-digit growth led by Research Services, the company faced significant headwinds from destocking of its largest manufacturing collaboration, increased competitive intensity, and the elimination of China+1 tailwinds following the U.S. BIOSECURE Act.
- · The AGM will be held on Wednesday, July 29, 2026 at 3:30 pm IST via Video Conferencing.
- · Cut-off date for remote e-voting is Wednesday, July 22, 2026; e-voting runs from July 24 to July 28, 2026.
- · Final dividend record date was Friday, June 26, 2026; payment within 30 days of AGM approval.
- · 97% of total hazardous and non-hazardous waste recycled; 92% energy procured from renewable sources.
- · Peter Bains will step down as MD & CEO at the end of June 2026; Siddharth Mittal will succeed him.
- · The U.S. BIOSECURE Act eliminated short-term China+1 tailwinds; U.S. Most Favored Nation and Inflation Reduction Act influenced MNCs to rebalance manufacturing supply chains toward the USA.
- · Competitive intensity is increasing notably in China, Asia, and India.
02-07-2026
Dipna Pharmachem reported a strong annual performance for FY26, with total income rising 3.3% to ₹12,910.87 Lakhs and net profit surging 170.2% to ₹263.19 Lakhs. However, the quarterly results for Q4 FY26 showed a sharp decline: revenue from operations fell to ₹202.49 Lakhs from ₹5,351.72 Lakhs in Q3 FY26, and net profit dropped to ₹17.86 Lakhs from ₹104.21 Lakhs in the prior quarter. The Chemicals segment posted a loss of ₹61.08 Lakhs in Q4, while the Steel segment contributed a profit of ₹83.36 Lakhs.
- · The company adopted IND AS for the first time during FY26.
- · The company has two reportable segments: Chemicals and Steel.
- · Share warrant money received during FY26 was ₹1,827.01 Lakhs, contributing to equity.
- · Total assets more than doubled to ₹20,562.94 Lakhs from ₹13,238.03 Lakhs in FY25.
- · Cash flow from operations was negative at ₹1,832.23 Lakhs for FY26, compared to negative ₹919.46 Lakhs in FY25.
- · Finance costs decreased to ₹146.32 Lakhs in FY26 from ₹201.57 Lakhs in FY25.
- · The company's paid-up equity share capital increased to ₹2,628.92 Lakhs from ₹2,404.53 Lakhs due to a preferential issue of shares and warrants.
- · Earnings per share (basic) for FY26 stood at ₹1.00, up from ₹0.41 in FY25.
02-07-2026
UHM Vacation Ltd's Board of Directors approved audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026, with an unmodified audit opinion. The company also appointed M/s. Varun Kabra & Associates as Secretarial Auditor for five years (FY 2026-27 to FY 2030-31), subject to shareholder approval. No funds were raised through a public issue as of the reporting date, so Regulation 32 provisions were not applicable.
- · The company's securities were listed on June 11, 2026, but the reporting period is for the financial year ended March 31, 2026.
- · No funds were raised through the Public Issue as of March 31, 2026, making Regulation 32 of SEBI LODR not applicable.
- · The Board meeting commenced at 7:30 PM and concluded at 9:00 PM on July 2, 2026.
- · Varun Kabra holds LL.B. and M.Com. degrees and has over four years of experience in corporate laws and secretarial compliances.
02-07-2026
Khadim India Limited has informed the exchanges that its Board of Directors, in a meeting held on July 2, 2026, approved an alteration to the Articles of Association. The modification updates the clause related to the determination of price in case of a further issue of capital, and is subject to approval by the company's members.
- · The alteration relates specifically to the clause on price determination for further issue of capital under the Articles of Association.
- · The change is subject to member (shareholder) approval.
02-07-2026
Rajratan Global Wire Limited reported a 24% increase in revenue from operations to ₹1,15,650 Lakh in FY26 from ₹93,525 Lakh in FY25, driven by higher export sales and increased contributions from the Chennai facility. However, EBITDA margin declined to 12.10% from 13.57% and RoCE moderated to 13.53% from 14.72%, primarily due to higher raw material costs in the fourth quarter. The 38th Annual General Meeting is scheduled for July 24, 2026 via video conference.
- · Installed capacity in India stands at 1,32,000 TPA (Pithampur 72,000 TPA, Chennai 60,000 TPA); total combined with Thailand at 1,92,000 TPA.
- · Promoter group held 65.20% equity as of March 31, 2026.
- · Exports contributed 17% of revenues in FY26.
- · The Company has a wholly-owned US subsidiary established in 2024.
- · Dividend payout remained flat at ₹1,015 Lakh in FY26, same as FY25.
- · Debt/EBITDA increased to 2.31x from 1.87x, reflecting higher borrowings for working capital and capex.
02-07-2026
Dipna Pharmachem reported a strong annual performance for FY26, with total income rising 3.3% to ₹12,910.87 Lakhs and net profit surging 170.2% to ₹263.19 Lakhs. However, the Q4 FY26 quarter was extremely weak: revenue from operations collapsed to just ₹202.49 Lakhs (vs. ₹5,351.72 Lakhs in Q3 FY26) and the Chemicals segment posted a segment loss of ₹61.08 Lakhs. The company also adopted IND AS for the first time and raised ₹1,827.01 Lakhs through share warrants.
- · The company adopted IND AS for the first time during FY26, and the financial results have been prepared accordingly.
- · Share warrant money received during FY26 amounted to ₹1,827.01 Lakhs, contributing to a significant increase in equity.
- · Total assets grew to ₹20,562.94 Lakhs as at 31 Mar 2026 from ₹13,238.03 Lakhs a year earlier.
- · Cash and cash equivalents increased to ₹86.30 Lakhs from ₹42.57 Lakhs at the beginning of the year.
- · The company has two reportable segments: Chemicals and Steel.
- · Chemicals segment revenue declined 46.7% YoY to ₹5,819.19 Lakhs, and the segment swung from a profit of ₹124.30 Lakhs in FY25 to a loss of ₹512.35 Lakhs in FY26.
- · Steel segment revenue surged 348.5% YoY to ₹7,089.14 Lakhs, and segment profit jumped to ₹866.83 Lakhs from ₹17.72 Lakhs.
- · The company does not have any subsidiary.
- · No investor complaints were unresolved as of 31 Mar 2026.
02-07-2026
UHM Vacation Ltd's Board of Directors approved audited standalone and consolidated financial results for the half year and financial year ended March 31, 2026, with an unmodified audit opinion. The company also appointed M/s. Varun Kabra & Associates as Secretarial Auditor for a five-year term starting FY 2026-27, subject to shareholder approval. No funds were raised through a public issue as of the reporting date, so Regulation 32 provisions were not applicable.
- · The company's securities were listed on BSE on June 11, 2026 (Scrip Code: 544779, Scrip ID: UHMVL).
- · The Board meeting commenced at 7:30 PM and concluded at 9:00 PM on July 2, 2026.
- · The Secretarial Auditor appointment is for 5 consecutive years from FY 2026-27 to FY 2030-31.
- · Varun Kabra holds LL.B. and M.Com. degrees with over four years of experience.
02-07-2026
Laurus Labs Limited announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for a five-year term, effective July 2, 2026, following shareholder approval at the 21st Annual General Meeting. Both appointees are unrelated to existing directors or key managerial personnel and are not debarred by any regulatory authority. No financial or operational metrics were disclosed in this filing.
- · The appointments were approved at the 21st Annual General Meeting held on July 2, 2026.
- · Dr. Shekhar Chintamani Mande holds DIN 10083454; Ms. Sutapa Banerjee holds DIN 02844650.
- · Both appointments are for a term of 5 consecutive years effective July 2, 2026.
- · The relevant details under SEBI regulations were previously submitted on April 30, 2026.
02-07-2026
Rajratan Global Wire Limited published its Integrated Annual Report for FY 2025-26, reporting consolidated revenue of ₹1,15,650 Lakhs, up 24% from ₹93,525 Lakhs in FY 2024-25, driven by higher export sales and increased volumes from the Chennai facility. However, EBITDA margin declined to 12.10% from 13.57% and RoCE moderated to 13.53% from 14.72%, primarily due to higher raw material costs in the fourth quarter. Net profit rose 19% to ₹7,011 Lakhs, while Debt/EBITDA increased to 2.31x from 1.87x on higher borrowings for working capital and capex.
- · The 38th Annual General Meeting is scheduled for July 24, 2026 at 3:00 PM IST via video conference.
- · Promoter group held 65.20% of equity as on March 31, 2026.
- · Exports accounted for 17% of revenues in FY 2025-26.
- · The Company has a wholly owned U.S. subsidiary established in 2024.
- · Installed capacity has grown from 60,000 TPA in FY 2015-16 to 1,92,000 TPA in FY 2025-26.
- · Dividend payout of ₹1,015 Lakhs was maintained in FY 2025-26, same as prior year.
02-07-2026
Nucleus Software Exports Limited published its Integrated Annual Report for FY 2025-26, reporting consolidated revenue of ₹876.03 crore (up 5.26% YoY) but a sharp decline in profitability: EBITDA fell 25.92% to ₹124.16 crore (14.17% of revenue vs 20.14% last year) and PAT dropped 28.38% to ₹116.74 crore (13.33% of revenue vs 19.59%). The company maintained a debt-free status with cash equivalents of ₹414.14 crore (46% of shareholders' funds), while employee costs and operating expenses rose significantly by 10.24% and 24.59% respectively.
- · Exceptional items of ₹21.95 crore were recorded in FY 2025-26 (none in prior year).
- · Consolidated other income decreased 3.17% to ₹64.16 crore from ₹66.26 crore.
- · Depreciation and amortization increased 11.34% to ₹16.49 crore.
- · Finance costs surged 88% to ₹1.41 crore.
- · Number of shareholders declined 11.3% from 44,686 to 39,648.
- · Market capitalisation dropped 9.97% to ₹1,902.53 crore from ₹2,113.13 crore.
- · Earnings per share fell 27.77% to ₹44.35 from ₹61.40.
- · Dividend per share remained flat at ₹12.50.
- · Book value per share increased 11.45% to ₹344.71 from ₹309.29.
- · The company remains debt-free.
- · 99.86% of shares are in dematerialized form.
- · The 37th Annual General Meeting is scheduled for July 27, 2026 via video conferencing.
- · Final dividend record date is July 10, 2026.
02-07-2026
Balkrishna Paper Mills Limited announced that all four resolutions proposed via postal ballot were approved by shareholders with requisite majority on July 2, 2026. The resolutions included a scheme for reduction of share capital (special resolution) and three ordinary resolutions approving material related party transactions with entities including Futuristic Concepts Media LLP, S P Finance and Trading Limited, and Sanchna Trading and Finance Limited. Notably, promoter Vishal Furnishings Ltd. inadvertently voted on three resolutions where it was interested, resulting in 9,005 votes being invalidated per Regulation 44.
- · The voting period for the postal ballot ran from June 3, 2026 at 9:00 AM IST to July 2, 2026 at 5:00 PM IST.
- · Resolution 1 (share capital reduction) passed with 99.94% of votes in favour and 0.06% against; promoter group voted 100% in favour.
- · Resolutions 2, 3, and 4 (material related party transactions) each passed with 99.42% of votes in favour and 0.58% against; promoters abstained from voting.
- · The cut-off date for eligibility was May 22, 2026.
- · Scrutinizer's report confirmed fair and transparent voting process.
02-07-2026
UHM Vacation Ltd (formerly UHM Vacation Private Ltd) held a Board meeting on July 2, 2026, approving audited standalone and consolidated financial results for the half-year and full year ended March 31, 2026, with an unmodified audit opinion. The company also appointed M/s. Varun Kabra & Associates as Secretarial Auditor for five years (FY2026-27 to FY2030-31), subject to shareholder approval. Notably, the company was listed on June 11, 2026, but since no public issue funds were raised as of March 31, 2026, Regulation 32 (fund utilization) was not applicable for the reporting period.
- · The Board meeting started at 7:30 PM and concluded at 9:00 PM on July 2, 2026.
- · The company's securities were listed on BSE on June 11, 2026 (Scrip Code: 544779, Scrip ID: UHMVL).
- · No funds were raised through a Public Issue as of March 31, 2026, so Regulation 32 (fund utilization) was not applicable.
- · The Secretarial Auditor appointment is for 5 consecutive years from FY2026-27 to FY2030-31, subject to shareholder approval.
- · Varun Kabra holds LL.B. and M.Com. degrees and has over four years of experience.
02-07-2026
Balkrishna Paper Mills Limited announced that all four resolutions proposed via postal ballot were passed with requisite majority. The resolutions included a special resolution for a scheme of reduction of share capital and three ordinary resolutions for material related party transactions with entities including Futuristic Concepts Media LLP, S P Finance and Trading Limited, and Sanchna Trading and Finance Limited. However, promoter Vishal Furnishings Ltd. inadvertently voted on three resolutions where it was interested, resulting in 9,005 votes being declared invalid for each of those resolutions.
- · The voting period for the postal ballot was from June 3, 2026, to July 2, 2026.
- · Record date (cut-off) for voting eligibility was May 22, 2026.
- · Promoter group did not vote on Resolution 1 (no interest) but held 19,315,802 shares (99.98% of outstanding).
- · On Resolutions 2, 3, and 4, promoter group did not vote due to interest, but promoter Vishal Furnishings Ltd. inadvertently cast 9,005 votes which were declared invalid.
- · Public non-institutional shareholders voted 15.98% to 15.99% of their shares on the resolutions, with overwhelming support (99.39% to 99.42% in favour).
- · Public institutional shareholders (27 shares) did not vote on any resolution.
02-07-2026
Dr. Agarwal’s Eye Hospital Limited announced that its shareholders have approved the scheme of amalgamation with Dr. Agarwal’s Health Care Limited, as directed by the NCLT. While the resolution passed with 89.87% votes in favour overall, the public shareholders were sharply divided with 48.10% votes against the scheme, indicating significant minority opposition. The scheme will now proceed for final sanction by the NCLT.
02-07-2026
Dr. Agarwal's Health Care Limited announced that its equity shareholders have approved the Scheme of Amalgamation with Dr. Agarwal's Eye Hospital Limited at an NCLT-convened meeting held on July 2, 2026. The resolution received overwhelming support with 99.97% of votes cast in favor, including unanimous support from the promoter group (100%) and near-unanimous support from public shareholders (99.96%). The scheme is now deemed passed as of July 2, 2026.
- · The NCLT convened meeting was held physically at The Music Academy, T.T.K. Road, Chennai.
- · The e-voting period ran from June 7, 2026 to July 1, 2026.
- · The record date for voting eligibility was June 3, 2026.
- · No promoter/promoter group was deemed interested in the resolution except to the extent of shareholding/common directorships.
- · Total outstanding shares of the company were 316,983,028.
02-07-2026
Balkrishna Paper Mills Limited announced that all four resolutions proposed via postal ballot (e-voting from June 3 to July 2, 2026) were passed with requisite majority. The resolutions included a special resolution for a scheme of reduction of share capital and three ordinary resolutions for material related party transactions with entities including Futuristic Concepts Media LLP, S P Finance and Trading Limited, and Sanchna Trading and Finance Limited. While the capital reduction resolution saw overwhelming support (99.94% of votes polled in favour), the related party resolutions received only 99.42% of public non-institutional votes in favour, with promoter votes excluded due to interest, and a small number of votes against (0.58%).
- · The voting period for the postal ballot was from June 3, 2026 (9:00 AM IST) to July 2, 2026 (5:00 PM IST).
- · Record date (cut-off) for e-voting eligibility was May 22, 2026.
- · For Resolution 1 (capital reduction), promoter group voted 100% in favour (19,312,178 votes), while public non-institutional votes were 99.39% in favour (2,051,251) and 0.61% against (12,683).
- · For Resolutions 2,3,4 (related party transactions), promoter group did not vote (0 votes) as they were interested parties; public non-institutional votes were 99.42% in favour (2,050,170) and 0.58% against (12,038).
- · Promoter Vishal Furnishings Ltd. inadvertently cast 9,005 votes for Resolutions 2,3,4, which were treated as invalid due to interest.
- · Total voter turnout for Resolution 1 was 66.35% (21,376,112 votes polled out of 32,219,532 shares).
- · Total voter turnout for Resolutions 2,3,4 was only 6.40% (2,062,208 votes polled) because promoter votes were excluded.
- · The scrutinizer's report was issued by Prasen Naithani of P. Naithani & Associates.
02-07-2026
Bajaj Electricals Limited announced the appointment of Tiny Sengupta as Chief Marketing Officer (CMO), effective June 29, 2026. The company reported a turnover of INR 4,462 crores for FY 25-26. The filing does not include any financial results or performance comparisons.
- · Tiny Sengupta brings over 22 years of global experience across Healthcare and FMCG.
- · She most recently served as Country Director, Vision Care, Johnson & Johnson India.
- · She has won several accolades, including 'Business Woman of the Year & Visionary Leader' at ET Ascent 2023.
- · She was recognized among 'Asia's Most Inspirational Women in Leadership 2022' by House of Rose Professional.
02-07-2026
Nucleus Software Exports Limited filed its Integrated Annual Report for FY 2025-26, reporting consolidated revenue of ₹876.03 crore (up 5.26% YoY from ₹832.25 crore). However, profitability declined sharply: EBITDA fell 25.92% to ₹124.16 crore (14.17% of revenue vs 20.14% prior), and PAT dropped 28.38% to ₹116.74 crore (13.33% of revenue vs 19.59% prior), impacted by a 13.12% rise in total expenses and an exceptional item of ₹21.95 crore. The company remains debt-free with cash equivalents of ₹414.14 crore (46% of shareholders' funds).
- · The 37th Annual General Meeting is scheduled for Monday, July 27, 2026 at 10:00 AM IST via Video Conferencing.
- · Cut-off date for e-Voting is Monday, July 20, 2026; remote e-Voting runs from July 22 to July 26, 2026.
- · Final dividend record date is Friday, July 10, 2026.
- · Dividend per share maintained at ₹12.50 for FY 2025-26 (same as prior year).
- · Earnings per share (EPS) fell to ₹44.35 from ₹61.40 in FY 2024-25.
- · Book value per share increased to ₹344.71 from ₹309.29.
- · Market capitalisation declined to ₹1,902.53 crore from ₹2,113.13 crore.
- · Number of shareholders decreased to 39,648 from 44,686.
- · Exceptional items of ₹21.95 crore impacted profitability in FY 2025-26.
- · Company remains debt-free with cash equivalents of ₹414.14 crore (46% of shareholders' funds).
02-07-2026
Reliance Power Limited has received a penalty order of ₹2,44,93,394 from the Income Tax Department under Section 271(1)(c) of the Income-tax Act, 1961 for Assessment Year 2016-17, relating to disallowance under Section 14A read with Rule 8D and a transfer pricing adjustment. The company states there is no impact on its financial, operational, or other activities beyond the penalty amount, and plans to appeal the order based on legal advice, expecting a favorable outcome.
- · Penalty relates to disallowance under Section 14A read with Rule 8D and a transfer pricing adjustment.
- · Order dated June 29, 2026, received on July 02, 2026.
- · Company plans to appeal the order before the Appellate Authorities and reasonably expects a favorable order based on merits, prevailing law, and legal advice.
02-07-2026
Delhivery Limited received a tax demand order under Section 74 of the CGST/Tamil Nadu GST Act for FY 2023-24, confirming a total demand of ₹27,64,150 in tax, ₹10,83,698 in interest, and ₹27,64,150 in penalty, totaling approximately ₹66,11,998. The demand arises from disallowance of input tax credit. The company states there is no material impact on financials, operations, or other activities.
- · Order received under Section 74 of CGST/Tamil Nadu GST Act for FY 2023-24.
- · Date of receipt of order: June 27, 2026.
- · Violation: disallowance of input tax credit.
- · Company states no material impact on financials, operations, or other activities.
- · Company was reviewing the order and evaluating next steps, causing a brief delay in disclosure.
02-07-2026
Nucleus Software Exports Limited has announced a record date of July 10, 2026 for its 37th Annual General Meeting and the proposed final dividend of ₹12.50 per equity share for FY 2025-26. The dividend is subject to shareholder approval at the AGM and, if approved, will be paid within 30 days of declaration.
- · Record Date: Friday, July 10, 2026
- · Dividend Payment Date: On or before 30 days from the date of declaration (if approved)
- · Dividend Financial Year: April 1, 2025 to March 31, 2026
- · Face Value: ₹10 per equity share
02-07-2026
Kfin Technologies Limited announced the cessation of Mr. Ramesh Ramchandran as Senior Vice President – Customer Relationship Management (Senior Management Personnel) effective July 02, 2026, as he transitions to the role of Principal Officer at KFin Global Technologies (IFSC) Limited, a wholly-owned subsidiary. This is an internal movement within the group and does not involve any financial impact or change in the company's operations.
- · Mr. Ramesh Ramchandran's cessation is effective July 02, 2026, at around 04:25 p.m. IST.
- · He will assume the role of Principal Officer at KFin Global Technologies (IFSC) Limited, a wholly-owned subsidiary.
- · The cessation letter was dated June 30, 2026.
- · No financial details or performance metrics are disclosed in this filing.
02-07-2026
CARE Ratings reaffirmed Riba Textiles Ltd.'s long-term bank facilities at 'CARE BBB; Stable' and short-term facilities at 'CARE A3+', removing the 'Credit Watch with Negative Implications' after the U.S. reduced tariffs on textiles from 50% to 10%. However, the company's operating income declined 13.7% YoY to ₹255.38 crore in FY26 from ₹295.86 crore in FY25, while total debt increased to ₹75.88 crore from ₹61.39 crore, raising the overall gearing to 0.72x from 0.63x.
- · The company's operating cycle elongated to 95 days in FY26 from 72 days in FY25, driven by higher inventory holding (54 days vs 35 days) and slower collections (60 days vs 53 days).
- · Total debt increased 23.6% YoY to ₹75.88 crore, primarily due to higher working capital borrowings and incremental term debt.
- · Interest coverage declined to 3.50x in FY26 from 3.85x in FY25.
- · The company's current ratio stood at 1.19x and quick ratio at 0.68x as on March 31, 2026.
- · Average utilization of working capital borrowings for the last twelve months ended May 2026 was ~65%.
- · Free cash and bank balance was ₹4.15 crore as on March 31, 2026.
- · Expected gross cash accruals for FY27 are approximately ₹13-14 crore against debt repayment obligations of ₹8.00 crore.
- · The company has initiated measures to diversify its customer base, particularly into Latin American markets, reducing U.S. dependence from ~30% of export revenues historically to 20% of total sales in FY26.
- · Top 10 customers accounted for approximately 34% of total operating income in FY26, indicating moderate customer concentration.
- · The company's installed capacity is 8,400 metric tonnes per annum for terry towels and related products.
02-07-2026
JSW Steel Limited released its Integrated Annual Report for FY 2025-26, reporting consolidated revenue from operations of ₹1,85,470 crore (up 10% YoY) and consolidated net profit of ₹25,508 crore (up 631% YoY). However, capacity utilisation declined to 92% from 91% in the prior year, and consolidated crude steel production grew only 8% to 30.14 MnT, while value-added and special products (VASP) sales grew 14% to 17.57 MnT. The company reduced net debt by approximately ₹22,693 crore during the year, demonstrating improved financial discipline.
- · Consolidated steel sales volume grew 12% to 29.63 MnT.
- · Specific energy consumption reduced to 5.55 Gcal/tcs.
- · Safety observations exceeded 5 lakh.
- · Dividend per share declared at ₹7.10.
- · Earnings per share (diluted) at ₹91.25.
- · Recognised as a worldsteel Sustainability Champion for the 8th consecutive year.
- · Ranked #1 in the Global Steel Sector in S&P CSA 2025.
- · BPSL steel business transferred to JSW JFE Steel Ltd. on March 27, 2026.
- · Non-financial disclosures cover >90% of revenue.
- · Net debt reduced by approximately ₹22,693 crore during FY 2025-26.
02-07-2026
MTAR Technologies Limited has informed stock exchanges about scheduled analyst and institutional investor meetings in Singapore from July 7 to July 10, 2026. The meetings will be held in-person or virtually, in one-on-one or group formats, during 9:00 AM to 5:30 PM SGT. This is a routine disclosure under SEBI LODR regulations and does not contain any financial results or material business updates.
02-07-2026
JSW Steel Limited has issued the notice for its 32nd Annual General Meeting (AGM) to be held on July 24, 2026, via video conference. The agenda includes adoption of financial statements, declaration of a dividend of ₹7.10 per equity share, re-appointment of directors, and several special resolutions, including a ₹7,000 crore issuance of specified securities and material related party transactions worth ₹24,380 crore with JSW JFE Steel Limited. The filing also covers ratification of cost auditor remuneration and appointment of independent directors.
- · The AGM will be held on Friday, July 24, 2026 at 11:00 a.m. IST via Video Conference/Other Audio-Visual Means.
- · The company proposes to issue specified securities (Non-Convertible Debentures with warrants, equity shares, convertible securities) up to ₹7,000 crore to Qualified Institutional Buyers.
- · Material related party transactions with JSW JFE Steel Limited amount to ₹24,380 crore (company level) and USD 2,622 million (subsidiary level).
- · Ms. Fiona Jane Mary Paulus is proposed for re-appointment as Independent Director for a second term from May 27, 2027 to May 26, 2032.
- · Mr. Devopam Bajpai is proposed for appointment as Independent Director for a term from July 2, 2026 to July 1, 2031.
- · Cost auditor remuneration for FY 2026-27 is ₹25,00,000 plus taxes and out-of-pocket expenses.
02-07-2026
Dr. Agarwal's Eye Hospital Limited held a meeting of its sole secured creditor on July 2, 2026, to approve a Scheme of Amalgamation with Dr. Agarwal's Health Care Limited. The resolution was passed with the requisite special majority, as the single secured creditor present voted in favor. The meeting, convened by order of the NCLT Chennai Bench, concluded in 15 minutes with full creditor approval.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai – 600 014.
- · The meeting lasted from 10:30 A.M. to 10:45 A.M. IST (15 minutes).
- · Voting was conducted through e-voting at the venue and by polling paper for valid proxy holders.
- · The resolution was a special majority resolution under Section 230(6) of the Companies Act, 2013.
02-07-2026
Dr. Agarwal's Health Care Limited held a meeting of its secured creditors on July 2, 2026, convened by the NCLT Chennai Bench, to consider and approve a Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited with the company. The meeting had only 2 out of 3 secured creditors present, but the quorum of 1 was met, and the resolution was duly transacted. The filing confirms procedural compliance but does not disclose the voting outcome or any dissent, leaving the scheme's approval status unclear.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai on July 2, 2026 at 3:00 PM IST.
- · The NCLT order convening the meeting was dated May 5, 2026 (Company Application No. CA(CAA)/19/CHE/2026).
- · The resolution required a special majority as prescribed under section 230(6) of the Companies Act, 2013.
- · Voting was conducted through e-voting at the venue and polling paper for proxy holders; remote e-voting was kept open during the meeting.
- · The meeting concluded at 3:15 PM IST, lasting only 15 minutes.
02-07-2026
JSW Steel Limited has submitted the Integrated Annual Report for FY 2025-26 to stock exchanges and informed shareholders about the upcoming 32nd Annual General Meeting (AGM) scheduled for July 24, 2026, at 11:00 a.m. IST via video conferencing. The report is accessible via a weblink on the company's website and stock exchange portals, with key AGM dates including a record date of July 7, 2026, e-voting from July 21-23, 2026, and dividend payment on July 28, 2026, if approved. No financial results or performance metrics are disclosed in this filing.
- · AGM scheduled for Friday, July 24, 2026 at 11:00 a.m. IST via VC/OAVM.
- · Record date for AGM is Tuesday, July 7, 2026.
- · Last date for TDS exemption forms submission: Monday, July 13, 2026.
- · Cut-off date for e-voting: Friday, July 17, 2026.
- · E-voting runs from Tuesday, July 21, 2026 (09:00 a.m.) to Thursday, July 23, 2026 (5:00 p.m.).
- · Dividend payment date, if approved: Tuesday, July 28, 2026.
- · Shareholders without registered email receive this letter; they can register via KFin or DPs.
02-07-2026
Pajson Agro India Ltd has informed the exchange that BSE levied a fine of ₹5,000 (plus GST) for non-compliance with Regulation 23(9) of the Listing Regulations due to a one-day delay in uploading the XBRL file for Related Party Transactions. The company states the delay was inadvertent, caused by a technical error in the XBRL sheet, and has remitted the fine on July 2, 2026. The company confirms no other financial, operational, or activity impact beyond the fine amount.
- · The fine was levied for non-compliance with Regulation 23(9) of the SEBI Listing Regulations.
- · The XBRL filing for Related Party Transactions was submitted one day after the PDF version of the financial information was submitted to the exchange.
- · The company has remitted the fine amount of ₹5,000 plus GST on July 2, 2026.
- · The company states there is no other impact on financials, operations, or other activities beyond the fine.
02-07-2026
Dr. Agarwal's Health Care Limited announced that secured creditors have approved the scheme of amalgamation between Dr. Agarwal's Eye Hospital Limited and the company, as per the consolidated scrutinizer's report dated July 2, 2026. The meeting convened by NCLT resulted in the resolutions being passed by the requisite majority, with no mention of dissent or rejection.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai on July 2, 2026 at 3:00 PM IST.
- · The NCLT Order appointing Shri Shivam Parashar as Scrutinizer was dated May 5, 2026.
- · Facilities provided included remote e-voting, e-voting at the venue, and voting via polls.
- · The resolutions were deemed passed as on July 2, 2026.
02-07-2026
Dr. Agarwal's Eye Hospital Limited announced that its secured creditors have approved the Scheme of Amalgamation with Dr. Agarwal's Health Care Limited at a meeting convened by the NCLT on July 2, 2026. The resolution was passed with the requisite majority, and the scheme is now subject to final sanction by the NCLT. No financial figures or voting percentages were disclosed in the filing.
- · The NCLT convened meeting was held on July 2, 2026, at The Music Academy, Chennai.
- · The remote e-voting period ran from June 7, 2026, to July 1, 2026.
- · The cut-off date for voting eligibility was December 31, 2025.
- · The requisite quorum of 1 secured creditor was present at the meeting.
- · The scheme is between Dr. Agarwal's Eye Hospital Limited (transferor) and Dr. Agarwal's Health Care Limited (transferee).
02-07-2026
Dr. Agarwal's Eye Hospital Limited held an NCLT-convened meeting of unsecured creditors on July 02, 2026, to consider and approve the Scheme of Amalgamation with Dr. Agarwal's Health Care Limited. The meeting, chaired by Shri Kanwal Jeet Arora, achieved the required quorum of 30 unsecured creditors out of a total of 371, and the resolution was passed by special majority. The results of voting are pending the Scrutinizer's consolidated report.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai – 600 014.
- · The NCLT order date for convening the meeting was May 05, 2026.
- · The record date for unsecured creditors was Wednesday, December 31, 2025.
- · The required quorum was 30 unsecured creditors as prescribed by the NCLT.
- · Voting was conducted through e-voting at the venue and polling papers for proxy holders.
- · The meeting started at 11:30 A.M. (IST) and concluded at 12:05 P.M. (IST).
02-07-2026
Dr. Agarwal's Eye Hospital Limited announced that its unsecured creditors have approved the Scheme of Amalgamation with Dr. Agarwal's Health Care Limited at a meeting convened by the NCLT on July 02, 2026. The resolution was passed with the requisite majority, moving the merger process forward. No financial figures or performance metrics were disclosed in this filing.
- · The NCLT convened meeting of unsecured creditors was held on July 02, 2026 at The Music Academy, T.T.K. Road, Chennai.
- · Remote e-voting was open from June 07, 2026 (09:00 AM IST) to July 01, 2026 (05:00 PM IST).
- · The cut-off date for determining eligible unsecured creditors was December 31, 2025.
- · The Scheme involves amalgamation of Dr. Agarwal's Eye Hospital Limited (Transferor Company) into Dr. Agarwal's Health Care Limited (Transferee Company).
- · The NCLT had appointed Shri Sriram Ananth as Scrutinizer via order dated May 05, 2026.
- · Notice of the meeting was dispatched on June 01, 2026 via electronic mode and speed post, and advertised in Business Standard (English) and Makkal Kural (Tamil).
02-07-2026
Dr. Agarwal's Health Care Limited convened a meeting of its unsecured creditors on July 2, 2026, pursuant to an NCLT order dated May 5, 2026, to consider and approve a Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited with the company. The meeting initially lacked the required quorum of 30 unsecured creditors and was adjourned, then resumed with voting conducted via e-voting and polling papers. The resolutions were duly transacted, but the outcome and vote counts are not disclosed in this filing.
- · The NCLT order was dated May 5, 2026, with Company Application No. CA(CAA)/19/CHE/2026.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai.
- · The meeting initially lacked the required quorum of at least 30 unsecured creditors/proxies and stood adjourned briefly.
- · Voting was conducted through e-voting at the venue and polling papers for proxy holders; remote e-voting remained open during the meeting.
- · The meeting concluded at 5:19 PM IST.
02-07-2026
Dr. Agarwal's Health Care Limited announced that its unsecured creditors have approved the Scheme of Amalgamation between Dr. Agarwal's Eye Hospital Limited and Dr. Agarwal's Health Care Limited, as confirmed by the Scrutinizer's Consolidated Report. The meeting was convened by the NCLT on July 02, 2026, and the resolution was passed with the requisite majority. No financial details or dissenting votes were disclosed in the filing.
- · The NCLT convened meeting of Unsecured Creditors was held on July 02, 2026 at 4:45 PM IST at The Music Academy, Chennai.
- · The NCLT Order appointing the Scrutinizer was dated May 05, 2026.
- · The Scheme was approved by the requisite majority of unsecured creditors and deemed passed as of July 02, 2026.
- · The company provided remote e-voting, e-voting at venue, and voting via polls for the transaction.
Get daily alerts with 10 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 50 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Pre-Market Regulatory Roundup
🇮🇳 More from India
View all →June 26, 2026
India Upcoming Corporate Actions BSE NSE — June 26, 2026
India Upcoming Corporate Actions BSE NSE
June 26, 2026
India Quarterly Results BSE NSE Announcements — June 26, 2026
India Quarterly Results BSE NSE Announcements
June 25, 2026
India Quarterly Results BSE NSE Announcements — June 25, 2026
India Quarterly Results BSE NSE Announcements
June 25, 2026
India Upcoming Corporate Actions BSE NSE — June 25, 2026
India Upcoming Corporate Actions BSE NSE